Completed OBSERVATIONAL NCT01435629

A Survey Collecting Data on Adult Height in Patients With Achondroplasia Treated With Somatropin

Open-label, Multicenter, Observational, Non-intervention Study to Retrospectively Evaluate the Efficacy of Norditropin® (Adult Height) in Patients With Achondroplasia/Hypochondroplasia Enrolled in the GH-1941 Study [Follow-up Survey]

Sponsor: Novo Nordisk A/S

Conditions Achondroplasia Genetic Disorder

Interventions somatropin

Updated 8 times since 2017 Last updated: May 4, 2017 Started: Nov 22, 2012 Primary completion: Dec 4, 2015 Completion: Dec 4, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Achondroplasia and Genetic Disorder and is currently completed. Novo Nordisk A/S leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 3 earlier versions

Jun 2017 — Apr 2018 [monthly]

Completed NA
Feb 2017 — Jun 2017 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Nov 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novo Nordisk A/S

Data source: Novo Nordisk A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tokyo, Japan